Rapid Dose Therapeutics Corp

As of May 31, 2026, Rapid Dose Therapeutics Corp carries a market capitalization of 15.55M, placing it among publicly traded companies globally. Its enterprise value stands at 20.67M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of May 31, 2026, Rapid Dose Therapeutics Corp has 135.18M shares outstanding.

These figures are as of May 31, 2026. The price-to-sales ratio is 5.98, and the price-to-book ratio stands at -2.06.

These figures are as of May 31, 2026. The EV/Sales ratio of 8.03 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 20.67M versus a market cap of 15.55M, with the gap driven by net debt and cash on the balance sheet.

As of May 31, 2026, Rapid Dose Therapeutics Corp maintains a current ratio of 0.04, meaning it holds 0.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -68.19, indicating conservative leverage, while an interest coverage ratio of -1.09 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended May 31, 2026. Return on assets (ROA) is negative at -89.12, reflecting losses generated across the asset base. Inventory turnover of 6.44 indicates how many times Rapid Dose Therapeutics Corp sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on September 2, 2026, Rapid Dose Therapeutics Corp's stock has declined approximately 50.00% over the past 52 weeks. The 50-day moving average sits at 0.18, while the 200-day moving average is 0.26.

Over the twelve months ended May 31, 2026, Rapid Dose Therapeutics Corp generated 2.58M in revenue and converted that into -3.17M in net income, yielding earnings per share of -0.02. EBITDA reached -1.39M, while operating income came in at -1.89M.

As of May 31, 2026, Rapid Dose Therapeutics Corp holds 14,653.00 in cash and equivalents against 5.14M in total debt, resulting in a net debt position of 2.94M. Total book value stands at -7.54M, with working capital of -8.39M providing operational flexibility.

Rapid Dose Therapeutics Corp produced 114,410.00 in operating cash flow over the twelve months ended May 31, 2026. After subtracting 2.55M in capital expenditures, free cash flow totaled 2.66M - equivalent to 0.02 per share.

Over the twelve months ended May 31, 2026, Rapid Dose Therapeutics Corp posted a gross margin of 49.83, reflecting its pricing power and cost economics. The operating margin of -73.59 and net profit margin of -123.09 provide insight into operational efficiency.

These figures cover the twelve months ended May 31, 2026. Free cash flow yield stands at 17.27, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 17.50, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Rapid Dose Therapeutics Corp shareholders.

As of May 31, 2026, Rapid Dose Therapeutics Corp has an Altman Z-Score of -25.27, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.